A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247)

NCT01622673 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Raltegravir
DRUG: TUMS® Ultra Strength
DRUG: MINTOX® Maximum Strength

Sponsor

Merck Sharp & Dohme LLC